帕尼培南/倍他米隆与亚胺培南/西司他丁治疗细菌感染疗效与安全性的Meta分析  

Meta-analysis of efficacy and safety of panipenem/betamipron with imipenem/cilastatin in the treatment of bacterial infection

作　　者：杨璐 庄雪梅 顾红燕 YANG Lu;ZHUANG Xue-mei;GU Hong-yan(Department of Pharmacy, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing Key Laboratory of Bio-eharacteristic Profiling for Evaluation of Rational Drug Use, Beij＇ing 100038;Department of Pharmacy, Center Hospital of Shandong Energy Zaozhuang Mining Group, Zaozhuang Shandong 277800)

机构地区：[1]首都医科大学附属北京世纪坛医院药剂科临床合理用药生物特征谱学评价北京市重点实验室,北京100038 [2]枣庄矿业集团中心医院药学部,山东枣庄277800

出　　处：《中南药学》2018年第4期543-547,共5页Central South Pharmacy

摘　　要：目的评价碳青霉烯类抗菌药物帕尼培南/倍他米隆与亚胺培南/西司他丁在细菌感染治疗中的疗效和安全性。方法利用计算机检索Pub Med、Medline、Cochrane library、中国期刊全文数据库、万方数据库和维普数据库等。2名研究员背对背提取资料,并对其方法学质量进行评价。纳入比较帕尼培南/倍他米隆与亚胺培南/西司他丁在相同给药剂量、给药方案下治疗细菌感染的疗效和安全性的随机对照试验(RCTs),采用Rev Man 5.2软件对入选试验进行Meta分析。结果共纳入12个随机对照试验,包括1261例细菌感染患者。Meta分析结果显示,帕尼培南/倍他米隆相比亚胺培南/西司他丁在治疗细菌感染中,临床有效率[OR=1.14,95%CI(0.85,1.53),P=0.38]与细菌清除率[OR=0.85,95%CI(0.60,1.20),P=0.36]差异均没有统计学意义。帕尼培南/倍他米隆与药物相关不良反应发生率为6.7%,亚胺培南/西司他丁为11.1%,两者差异[OR=0.59,95%CI(0.39,0.88),P=0.01<0.05]具有统计学意义。结论现有证据表明,帕尼培南/倍他米隆与亚胺培南/西司他丁在治疗细菌感染中疗效相当,前者安全性更高。Objective To compare the effectiveness and safety of panipenem/betamipron with imipenem/ cilastatin for bacterial infection. Methods The date were collected from the PubMed, Medline, Cochrane library, CNKI, Wanfang and Vip database. Two evaluators assessed the quality and reviewed the data independently. Randomized controlled trials comparing panipenem/betamipron with imipenem/cilastatin administered at the same dosage regimen in patients with bacterial infections were eligible for inclusion. Meta-analysis was conduct with Rev Man 5.2 software. Results Twelve randomized controlled trials comparing panipenem/betamipron with imipenem/cilastatin were analyzed, focusing on 1261 patients with bacterial infections. Meta-analysis found that, the clinical cure rate [OR = 1.14, 95%CI （0.85, 1.53）, P = 0.38] and bacterial eradication rate [OR = 0.85, 95%CI （0.60, 1.20）, P = 0.36] did not show significant difference between the two drugs. Drug- related adverse events occurred in 6.7% and 11.1% of panipenem/betamipron and imipenem/cilastatin patients respectively, with statistical difference [OR = 0,59, 95%CI （0.39, 0.88）, P = 0.01 〈 0.05]. Conclusion The evidence available suggests that the efficacy of panipenem/betamipron and imipenem/cilastatin for bacterial infection is similar; however, panipenem/betamipron is much safer.

关 键 词：帕尼培南/倍他米隆 亚胺培南/西司他丁 细菌感染 META分析 

分 类 号：R515[医药卫生—内科学]